The clinical trial result of HLB’s targeted anticancer medicine rivoceranib will be presented at the 2022 International Association for the Study of Lung Cancer (IASLC 2022), the company said Thursday.IASLC, the world’s largest symposium for lung cancer and other thoracic malignancy, will be held in
Despite Korean diagnostic companies pinning high hopes on monkeypox as a new growth engine after their big success during the Covid-19 pandemic, industry watchers are expressing doubt that their expectations would turn into a reality.The number of monkeypox infections has rapidly increased worldwide
The Seoul National University Hospital (SNUH) said Thursday that it launched a full-fledged study to develop digital treatments for abnormal behaviors and problems linked to autism spectrum disorder.Under the auspices of the Ministry of Science and ICT, the hospital will push the project using about
Fears of Covid-19 resurgence are spreading, but SK Bioscience has yet to apply for a lot release of SKYCovione, the first homegrown Covid-19 vaccine.On Wednesday, SK Bioscience confirmed SKYCovicone’s immune response to the Omicron variant BA.1 in extended phase 1 and 2 trials.The company gave two d
SK Biopharmaceuticals said it signed a $62 million licensing agreement to commercialize cenobamate (brand name: Xcopri), an anti-epileptic treatment, in Latin America.In a public filing on Thursday, the company said it licensed out cenobamate to Eurofarma Laboratorios SA for the commercialization of
MSD’s anti-PD-1 therapy Keytuda (pembrolizumab) won expanded indication to be used as neoadjuvant therapy in combination with chemotherapy before surgery in patients with triple-negative breast cancer (TNBC) and then continued as a single agent after surgery.This indication allows Keytruda to treat
Next-generation ALK inhibitors such as Alecensa (alectinib) and Lorviqua (lorlatinib) showed high activity in relapsed and refractory anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL), signaling their potential as a treatment option, a study said.No standard therapies exist for
GemVax & Kael, an immunotherapy drug developer, said on Wednesday that the company had secured safety in the non-clinical toxicity trials of GV1001, the company’s 16-amino-acid peptide immunotherapy drug for pancreatic cancer.New substances generally require various strict conditions to be met to be
The government has decided not to implement strict distancing rules, although new virus cases herald the advent of another Covid-19 wave.Instead, it will expand the targets of second booster shots to people in their 50s and those aged 18 and older with underlying conditions, quarantine officials sai
Bridge Biotherapeutics will present the phase 1 clinical trial’s result of BBT-176, the fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug, at the World Conference on Lung Cancer (WCLC) in Vienna next month.The conference organizers made public the abstract
JW Group said Wednesday that it signed an agreement with ARCH Venture Partners, a U.S. venture capital, to promote open innovation strategies with global bio companies.Under the accord, JW Group will receive ARCH Technical Service (ATS) programs, which provide promising biotech and technical informa
Biomarker-based new drug developer MedPacto has applied to the U.S. Food and Drug Administration for the investigational new drug (IND) clinical trial of Vactosertib as a solo therapy for recurrent and intractable osteosarcoma patients.This upcoming clinical trial, a phase 1/2 trial of Vactosertib a
Neoimmuntech said Wednesday that the U.S. Food and Drug Administration has granted an orphan drug designation (ODD) for NT-I7, its immunotherapy candidate that treats glioblastoma multiforme (GBM), a type of brain cancer.It was the fourth ODD designation for NT-I7. It also received ODD designations
Multicentric Castleman disease (MCD) is not cancer, but its prognosis is as poor as cancer.MCD is so rare and difficult to diagnose. As a result, many MCD patients get misdiagnosis and miss the right timing for treatment.Professor Jeon Young-woo of hematology at Yeouido St. Mary’s Hospital emphasize
SK Bioscience’s SKYCovione, Korea's first locally developed Covid-19 vaccine, has shown cross-neutralizing activity against Omicron variant BA.1 as a booster shot administered after the primary vaccination, the company said Wednesday."Amid the rising possibility of the resurgence of Covid-19, we hav
Boehringer Ingelheim and Eli Lilly aim to dominate the chronic heart failure market with Jardiance, a Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor drug, armed with an expanded indication in treating heart failure with preserved ejection fraction (HFpEF).HFpEF is a clinical syndrome in which pa
The National Human Rights Commission of Korea (NHRCK) recommended expanding telemedicine in correctional facilities.Prisons need to hire more physicians to guarantee inmates’ access to healthcare, but if it is not feasible, they should instead broaden contactless medical services, the human rights w
Pharmaceutical industry officials criticized the government for providing almost no support to nurture the local active pharmaceutical ingredient (API) sector.The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) and Rep. Nam In-soon of the Democratic Party hosted a debate on rev
A research team at the Korea Advanced Institute of Science and Technology (KAIST) team has developed nanomedicine for chemotherapy using an artificial glycolysis library platform.Various types of sugar chain aggregate surrounding the cell membrane called glycocalyx display different binding forces s
Korea’s daily Covid-19 tally surged to a two-month high of over 37,000 on Tuesday, as the BA.5, an Omicron subvariant, showed signs of becoming a dominant strain.The nation added 37,360 Covid-19 infections on Tuesday, bringing the total caseload to 18,561,861, the Korea Disease Control and Preventio